NET cases rise steadily as survival boosts prevalence; experts argue it’s no longer rare, driving urgent demand for more resources and treatments.
Back
A Multidisciplinary Approach to Neuroendocrine Tumors: From Somatostatin Receptor Imaging to Radioligand Therapy
Daniel M. Halperin, MD, of Winship Cancer Institute of Emory University; Jonathan R. Strosberg, MD, of Moffitt Cancer Center; and Simron Singh, MD, MPH, of Sunnybrook Odette Cancer Centre, discuss the multidisciplinary diagnosis and management of neuroendocrine tumors, from classification and somatostatin receptor PET imaging to peptide receptor radionuclide therapy and the alpha emitters on the horizon.
A Multidisciplinary Approach to Neuroendocrine Tumors: From Somatostatin Receptor Imaging to Radioligand Therapy
Episodes
All
All
Neuroendocrine tumors rise in incidence, often found incidentally, prompting multidisciplinary diagnosis, somatostatin receptor PET imaging, and evolving radioligand therapy options.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
4
Elranatamab Meets Phase 3 PFS End Point in R/R Myeloma After Anti-CD38 Therapy and Lenalidomide
5